Why Moderna Stock Rose Today
Shares of Moderna (NASDAQ: MRNA) climbed 3.6% on Thursday after the drugmaker announced the completion of enrollment for its COVID-19 vaccine study.
Moderna has enrolled 30,000 people for the phase 3 trial for its coronavirus vaccine candidate, mRNA-1273. The biotech noted that 42% of the participants are from groups deemed to be at high risk of severe COVID-19 disease, including more than 7,000 Americans over the age of 65 and 5,000 people who are younger but have chronic diseases, such as severe obesity and diabetes.
Moderna's stock rallied on Thursday as investors applauded its vaccine testing progress. Image source: Getty Images.
Source Fool.com
